104 related articles for article (PubMed ID: 22639843)
21. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma.
Shimizu Y; Umezawa S; Hasumi K
Ann Acad Med Singap; 1998 Sep; 27(5):650-6. PubMed ID: 9919334
[TBL] [Abstract][Full Text] [Related]
23. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
25. A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma.
Adachi S; Ogasawara T; Yamasaki N; Shibahara H; Kanazawa R; Tsuji Y; Takemura T; Koyama K
Jpn J Clin Oncol; 1999 Sep; 29(9):434-7. PubMed ID: 10563197
[TBL] [Abstract][Full Text] [Related]
26. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
27. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
28. [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
Shimoya K; Kunishige I; Okuno Y; Hayashi S; Komura H; Arimoto Y; Otsuki Y
Gan To Kagaku Ryoho; 2001 Jun; 28(6):845-8. PubMed ID: 11432356
[TBL] [Abstract][Full Text] [Related]
29. Prognostic implication of endometriosis in clear cell carcinoma of the ovary.
Orezzoli JP; Russell AH; Oliva E; Del Carmen MG; Eichhorn J; Fuller AF
Gynecol Oncol; 2008 Sep; 110(3):336-44. PubMed ID: 18639330
[TBL] [Abstract][Full Text] [Related]
30. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
[TBL] [Abstract][Full Text] [Related]
31. Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma.
Nishida M; Tsunoda H; Ichikawa Y; Yoshikawa H
Int J Clin Oncol; 2004 Oct; 9(5):403-5. PubMed ID: 15549593
[TBL] [Abstract][Full Text] [Related]
32. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
[TBL] [Abstract][Full Text] [Related]
33. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
[TBL] [Abstract][Full Text] [Related]
34. [Clinical characteristics of clear cell carcinoma of the ovary].
Shi M; Zhang Y; Shen K; Lang J; Huang H; Wu M
Zhonghua Fu Chan Ke Za Zhi; 2002 Mar; 37(3):161-3. PubMed ID: 11953086
[TBL] [Abstract][Full Text] [Related]
35. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy.
Bolis G; Villa A; Guarnerio P; Ferraris C; Gavoni N; Giardina G; Melpignano M; Scarfone G; Zanaboni F; Parazzini F
Cancer; 1996 Jan; 77(1):128-31. PubMed ID: 8630918
[TBL] [Abstract][Full Text] [Related]
36. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
[TBL] [Abstract][Full Text] [Related]
37. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.
Takano M; Kikuchi Y; Yaegashi N; Kuzuya K; Ueki M; Tsuda H; Suzuki M; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Sugiyama T
Br J Cancer; 2006 May; 94(10):1369-74. PubMed ID: 16641903
[TBL] [Abstract][Full Text] [Related]
38. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.
Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
J Gynecol Oncol; 2017 May; 28(3):e33. PubMed ID: 28382796
[TBL] [Abstract][Full Text] [Related]
40. The emerging world role of irinotecan in lung cancer.
Langer CJ
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
